文献速递耳科与耳神经

多奈哌齐对成人人工耳蜗使用者言语识别的影响:一项初步随机临床试验

Effect of Donepezil on Speech Recognition in Adult Cochlear Implant Users: A Pilot Randomized Clinical Trial.
PubMed 文献 · Ear Hear · 2026-09-23

9例完成方案,多奈哌齐组植入耳辅音-核-辅音词识别平均提高14.5分,超过10分临床显著性阈值,而安慰剂组下降0.8分。功能近红外光谱显示多奈哌齐增加左额叶皮层激活,提示胆碱能增强可能促进神经可塑性。

要点

  • 多奈哌齐组植入耳词识别提高14.5分,超过10分临床显著性阈值。
  • 安慰剂组词识别下降0.8分,组间效应量d=0.88。
  • 多奈哌齐组言语感知改善且聆听疲劳减少,左额叶皮层激活增加。

核心结论

  • 初步证据提示多奈哌齐可能改善人工耳蜗使用者的言语感知并促进神经可塑性。
  • 该初步研究样本量不足以确定多奈哌齐的临床疗效。

研究设计与样本

  • 纳入语后聋且设备使用至少6个月的成人人工耳蜗使用者。
  • 随机接受口服多奈哌齐5 mg或安慰剂每日一次,共90天。

主要发现

  • 多奈哌齐组植入耳辅音-核-辅音词识别平均提高14.5分,安慰剂组下降0.8分(d=0.88)。
  • 多奈哌齐组双耳词识别、句子识别和噪声下言语性能相对安慰剂组改善。
  • 多奈哌齐组言语感知问卷改善且聆听疲劳减少,人工耳蜗相关生活质量两组相似。
  • 神经影像显示显著组×时间交互效应,多奈哌齐增加噪声下言语任务中左额叶皮层激活(β=3.721,p<0.001)。
  • 所有参与者设备使用均增加,两组平均每日增加3.1小时。

关键数值与推荐

  • 主要结局为植入耳辅音-核-辅音词识别评分变化。
  • 临床显著性阈值定义为10分。
  • 次要结局包括双耳词识别、安静下句子识别、噪声下句子识别信噪比损失及问卷。

临床怎么用

  • 多奈哌齐作为辅助药物可能优化人工耳蜗使用者的言语识别 outcomes,但需进一步临床试验验证。
  • 研究期间鼓励增加设备使用,两组设备使用平均每日增加3.1小时。

局限性

  • 初步研究样本量小,仅9例完成方案并纳入分析。
  • 研究不足以确定多奈哌齐的临床疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Speech recognition outcomes following cochlear implantation vary widely among users, potentially due to differences in neuroplasticity. The cholinergic system plays a critical role in cortical reorganization and sensory learning; yet, its potential to enhance auditory plasticity in cochlear implant (CI) users has not been explored. The aim of this study is to investigate the effects of donepezil, a cholinergic agonist, on speech perception and cortical plasticity in adults with CIs. DESIGN: This pilot randomized clinical trial was conducted at a single tertiary academic center from April 2023 to December 2024. Adult CI recipients with a postlingual onset of deafness and at least 6 months of device experience were eligible for inclusion. Participants were randomized to oral donepezil 5 mg (DPZ) or placebo (PL) daily for 90 days. Both groups were encouraged to increase their daily device use during the study. The primary outcome measure was the change in consonant-nucleus-consonant word recognition scores for the implanted ear. Secondary outcomes included binaural word recognition, sentence recognition in quiet, signal to noise ratio loss for sentence recognition in noise, and questionnaires related to hearing satisfaction, listening fatigue, and quality of life. The questionnaires included the Speech, Spatial, and Quality of Hearing Scale, Vanderbilt Fatigue Scale, and CI Quality of Life Profile. Cortical plasticity was assessed using functional near-infrared spectroscopy. RESULTS: Thirteen experienced CI users were enrolled in this pilot study, with nine completing the 90-day protocol and included in the group descriptive analyses (DPZ: n = 4, PL: n = 5). Four participants (45%) were female, and the median age was 68 years. All study participants increased their device use, with a mean increase of 3.1 hr per day in both groups. Donepezil treatment was associated with a 14.5-point increase in mean CI-only consonant-nucleus-consonant word recognition, surpassing the 10-point threshold for clinical significance, whereas the placebo group decreased by 0.8 points (d = 0.88). Binaural word recognition, sentence recognition, and speech-in-noise performance also improved in the DPZ group relative to PL. Subjective measures showed greater improvements in speech perception (Speech, Spatial, and Quality of Hearing Scale) and reduced listening fatigue (Vanderbilt Fatigue Scale) in the DPZ group, while CI-related quality of life was similar between groups. Neuroimaging analyses revealed significant Group × Time interaction effects, with DPZ increasing left frontal cortex activation during a speech-in-noise task (β = 3.721, p < 0.001). CONCLUSIONS: These findings provide preliminary evidence that cholinergic enhancement with donepezil may improve speech perception and facilitate neuroplasticity in multisensory and cognitive brain regions in CI users. In addition, the neuroimaging analyses support cholinergic-induced neuroplasticity with DPZ treatment. While this pilot study was underpowered to determine the clinical efficacy of donepezil, pharmacological interventions like donepezil represent a promising novel approach to optimizing CI outcomes, and we offer recommendations for future clinical trials in this population.

来源:Ear Hear,查看原文。版权归原作者所有。

引用

  1. Kunnath AJ, Moberly AC, Wallace MT, et al. Effect of Donepezil on Speech Recognition in Adult Cochlear Implant Users: A Pilot Randomized Clinical Trial. Ear Hear. 2026. PMID: 42776967. doi:10.1097/AUD.0000000000001888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。